According to other research findings, combining PI3K/AKT/mTOR inhibitors with ICIs (which include PD-1 inhibitors in parallel with CTLA-4 inhibitors) or other anti-tumor immunotherapy may enable patients to obtain the best efficacy [91]. This evidence concerns the gene MTOR and neoplasm.